argenx Investor Relations Material
Latest events
Status Update
argenx
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from argenx SE
Access all reports
argenx SE is a biotechnology firm based in Amsterdam, the Netherlands, specializing in the development of innovative therapies for autoimmune diseases. The company has developed a range of antibody-based medicines focusing on severe autoimmune conditions. Its flagship product, efgartigimod, targets various autoimmune disorders including myasthenia gravis and immune thrombocytopenia. argenx SE also collaborates with several partners to expand its research and development capabilities in immunology and oncology, highlighting its engagement in strategic alliances to advance its pipeline of therapeutic antibodies. The company is headquartered in Amsterdam, the Netherlands, and its shares are listed on the NASDAQ.
Key slides for argenx SE
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ARGX
Country
🇧🇪 Belgium